ReviewProgress in neurobiology2019
Chronotherapies for Parkinson's disease.
Review in Progress in neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Exercise as a potent antidepressant intervention in Parkinson's disease: a systematic review and meta-analysis of randomised controlled trials.Frontiers in psychology · 2026Pooled it
- Dementia and Sleep Disorders: The Effects of Drug Therapy in a Systematic Review.International journal of molecular sciences · 2025Pooled it
- Time vortex: the circadian-dopaminergic dialogue in Parkinson's disease.NPJ Parkinson's disease · 2026Review
- A feasibility open-label clinical trial utilizing second-generation artificial intelligence based on the constrained-disorder principle in patients with Parkinson's disease.IBRO neuroscience reports · 2026Article
- Circadian re-set repairs long-COVID in a prodromal Parkinson's parallel: a case series.Journal of medical case reports · 2024Article
- Article
- Efficacy of biologically-directed daylight therapy on sleep and circadian rhythm in Parkinson's disease: a randomised, double-blind, parallel-group, active-controlled, phase 2 clinical trial.EClinicalMedicine · 2024Article
- Targeting sleep and the circadian system as a novel treatment strategy for Parkinson's disease.Journal of neurology · 2024Article
- Molecular characterization of the circadian clock in patients with Parkinson's disease-CLOCK4PD Study protocol.PloS one · 2024Article
- Fighting Against the Clock: Circadian Disruption and Parkinson's Disease.Journal of movement disorders · 2024Article
- Review
- Circadian disruption and sleep disorders in neurodegeneration.Translational neurodegeneration · 2023Review
- Circadian rhythms in the blood-brain barrier: impact on neurological disorders and stress responses.Molecular brain · 2023Review
- Blue light exposure-dependent improvement in robustness of circadian rest-activity rhythm in aged rats.PloS one · 2023Article
- Chronobiology of Parkinson's disease: Past, present and future.The European journal of neuroscience · 2023Review
- Melatonin ameliorates Parkinson's disease via regulating microglia polarization in a RORα-dependent pathway.NPJ Parkinson's disease · 2022Article
- Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models.Molecular medicine reports · 2022Article
- Circadian rhythms in neurodegenerative disorders.Nature reviews. Neurology · 2022Review
- Circadian Rhythms, Disease and Chronotherapy.Journal of biological rhythms · 2021Review
- Defining circadian disruption in neurodegenerative disorders.The Journal of clinical investigation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 5 countries.
Funding
Abstract
Parkinson's disease (PD) is the second-most common progressive neurodegenerative disorder. Although the clinical diagnosis of PD is still based on its cardinal motor dysfunctions, several non-motor symptoms (NMS) have been established as integral part of the disease. Unlike motor disorders, development of therapies against NMS are still challenging and remain a critical unmet clinical need. During the last decade, several studies have characterised the molecular, physiological and behavioural alterations of the circadian system in PD patients. As a consequence, and given the ubiquitous nature of circadian rhythms in the entire organism, the biological clock has emerged as a potential therapeutic target to ease suffering from both motor and NMS in PD patients. Here we discuss the emerging field of using bright light, physical exercise and melatonin as chronotherapeutic tools to alleviate motor disorders, sleep/wake alterations, anxiety and depression in PD patients. We also highlight the potential of these readily available therapies to improve the general quality of life and wellbeing of PD patients. Finally, we provide specific data- and mechanisms-driven recommendations that might help improve the therapeutic benefit of light and physical exercise in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.